Home/Pipeline/IBD98-M

IBD98-M

Inflammatory bowel disease

PreclinicalActive

Key Facts

Indication
Inflammatory bowel disease
Phase
Preclinical
Status
Active
Company

About Holy Stone Healthcare

Taiwan biotech leveraging hyaluronic‑acid biopolymers for targeted brain, eye, and tumor drug delivery.

View full company profile

Other Inflammatory bowel disease Drugs

DrugCompanyPhase
DVI-001DivamicsPreclinical
DVI-002DivamicsPreclinical
Turq-101Turquoise BiotechnologiesPreclinical
GS-4875GileadPhase 2
Function-based Consortium for IBDPharmaBiomePre-clinical
Galapagos CollaborationScipher MedicineDiscovery/Pre-clinical
IBD SubclassificationBio-MeResearch
Anti-iRhom2 antibodiesSciRhomPre-clinical
IBD Multi-omics DatasetOvation.ioCommercial
Noa‑001Noa TherapeuticsPreclinical
InflectraEMSPhase 3
IW-601ImmuneWalk TherapeuticsPreclinical